I recognize that while a lot of you busy biotech folk subscribe to BioWorld Today, I am probably one of the only people who actually reads every single word of the paper every single day. In doing so, I often come across really cool companies doing really cool stuff that you might have missed if you were just scanning the headlines for news related to one particular indication or another. So here’s a shout-out to a few of the coolest little companies I’ve stumbled on recently: Kingdoms Cross Station: NovaDigm Therapeutics Inc. just popped on the radar at ICAAC with...
While multidrug-resistant superbugs like methicillin-resistant Staphylococcus aureus (MRSA) and NDM-1 always steal the spotlight at the annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), one topic that tends to fly under the radar is antifungals.
One place you wouldn't expect to hear debate about drug pricing is among the antibiotics experts gathered in Chicago this month for the 2011 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Antibiotics are, after all, about as cheap as a drug class can be.
PharmAthene Inc. scored a stunning victory in its five-year legal battle against SIGA Technologies Inc., with the Delaware Court of Chancery awarding PharmAthene half of the net profits from SIGA's smallpox drug ST-246, subject of a government contract worth up to $2.8 billion.
The proposed merger of AMAG Pharmaceuticals Inc. and Allos Therapeutics Inc. has raised eyebrows from the start, but both firms remain committed to closing the deal, allowing neither criticism nor competing offers to stand in their way.
Tokai Pharmaceuticals Inc. is expected to announce Tuesday that it has raised $23 million in a Series D follow-on round to fund Phase IIb trials of triple-acting prostate cancer drug galeterone (TOK-001).
After a dozen or so disappointing biotech drug launches, investors have come to fear such events – a mentality some analysts argue isn't warranted across the board, particularly in light of new analyses that attempt to prospectively separate the commercial frontrunners from the flops.
Curis Inc. could soon collect an $8 million milestone payment from partner Genentech Inc., assuming the FDA accepts the newly filed new drug application (NDA) for vismodegib (RG3616/GDC-0449) in advanced, inoperable basal cell carcinoma (BCC).
